Amedisys Expands Its Board of Directors with Appointment of KKR’s Nathaniel M. Zilkha

  Amedisys Expands Its Board of Directors with Appointment of KKR’s Nathaniel
  M. Zilkha

Business Wire

BATON ROUGE, La. -- March 27, 2014

Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health and
hospice care companies, today announced the appointment of Nathaniel M. Zilkha
to the Company’s Board of Directors. Mr. Zilkha is a Member of the general
partner of KKR & Co. L.P. (together with its affiliates, “KKR”) and serves as
Head of KKR’s credit platform and as its Global Co-Head of Special Situations.
With this addition, the Company’s Board now comprises seven directors.

“We are pleased to welcome Nat Zilkha to our Board of Directors and look
forward to his contributions,” said Donald A. Washburn, Co-Chairman of the
Board. “The Amedisys Board and leadership team continues to be focused on
building value for our stockholders through improving the Company’s financial
performance, maintaining the highest quality, patient-centered services for
our patients across the country, and upholding our firm commitment to

“Creating stockholder value is a top priority for the Amedisys Board during
this period of transition for Amedisys as we align our business to the
sweeping change taking place across the health care industry,” said David R.
Pitts, Co-Chairman of the Board. “To that end, we welcome the expertise and
energy that Nat Zilkha will bring as the newest addition to our Board, and we
appreciate the vote of confidence that KKR has shown in our Company by virtue
of the investment that it has made.”

“I am delighted to join the Board of Amedisys,” said Mr. Zilkha. “We see great
potential in the home health and hospice space, and we believe Amedisys is
well positioned to capitalize on this opportunity. I look forward to working
with my fellow Board members and Amedisys’ senior management to position the
Company for strong future performance.”

About Amedisys:

Amedisys, Inc. (NASDAQ: AMED) is a “health care at home” company delivering
personalized home health and hospice care to more than 360,000 patients each
year. Amedisys is focused on delivering the care that is best for our
patients, whether that is home-based recovery and rehabilitation after an
operation or injury, care focused on empowering them to manage a chronic
disease, palliative care for those with a terminal illness, or hospice care at
the end of life. For more information about Amedisys, please visit:

We use our company website as a channel of distribution for important company
information. Important information, including press releases, analyst
presentations and financial information regarding the Company is routinely
posted on and accessible on the “Investor Relations” subpage of our website,
which is accessible by clicking on the tab labeled “Investors” on our website
home page. We will also use our website to expedite public access to
time-critical information regarding the Company in advance of or in lieu of
distributing a press release or a filing with the Securities and Exchange
Commission (“SEC”) disclosing the same information. In addition, we make
available on the Investor Relations subpage of our website (under the link
“SEC filings”) free of charge our annual reports on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms
3, 4 and 5 and any amendments to those reports as soon as practicable after we
electronically file such reports with the SEC. Further, copies of our
Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct
and the charters for the Audit, Compensation, Nominating and Corporate
Governance, Quality of Care and Compliance and Ethics Committees of our Board
are also available on the Investor Relations subpage of our website (under the
link “Corporate Governance”).

Bio Attached

Member – Board of Directors

Mr. Zilkha joined KKR in 2007 and serves as Head of KKR’s credit platform and
as its Global Co-Head of Special Situations. As Head of Credit, he works
closely with the credit portfolio teams to help drive investment performance,
strategy, business development and coordination across the platform. He is a
member of the Leveraged Credit, Private Credit and Special Situations
Investment Committees as well as the KKR Asset Management Portfolio Management
Committee. He also spent time as a member of the Healthcare Private Equity
Team in KKR’s Menlo Park office. Prior to joining KKR, Mr. Zilkha was a member
of the Principal Investment Area of Goldman, Sachs & Co., where he invested in
private equity and principal debt transactions. He is currently on the Boards
of Directors of Amedisys, Inc., the Winoa Group and QMH Limited. He was
formerly on the Boards of Directors of Harden Healthcare, Oriental Brewery and
Jazz Pharmaceuticals. Mr. Zilkha graduated cum laude from Princeton


Amedisys, Inc.
Media Contact:
Shannon McIntyre Hooper, 615-577-1124
Investor Contact:
David Castille, 225-299-3665
Director – Treasury/Finance
Press spacebar to pause and continue. Press esc to stop.